Results 301 to 310 of about 519,424 (339)

Discrete genetic subtypes and tumor microenvironment signatures correlate with peripheral T-cell lymphoma outcomes. [PDF]

Leukemia
Suehara Y, Sakamoto K, Fujisawa M, Fukumoto K, Abe Y, Makishima K, Suma S, Sakamoto T, Hattori K, Sugio T, Kato K, Akashi K, Matsue K, Narita K, Takeuchi K, Carreras J, Nakamura N, Chiba K, Shiraishi Y, Miyano S, Ogawa S, Chiba S, Sakata-Yanagimoto M.   +22 more
europepmc   +1 more source

Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma with novel FGFR1 fusion treated with pemigatinib. [PDF]

Blood Adv
Torres-Cabala CA, Yescas JA, Zhang Y, Huen A, Sumit G, Tefft K, Tang G, Curry JL, Gunther J, Dabaja B, Iyer S, Miranda RN, Choi J, Nardi V.   +13 more
europepmc   +1 more source

Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross‐over pharmacokinetic drug‐drug interaction study

Cancer Communications, EarlyView.
Niels Heersche, Daan A. C. Lanser, Esther Oomen‐de Hoop, Attila Içli, Peter de Bruijn, Marthe S. Paats, Elisabeth F. C. van Rossum, Stijn L. W. Koolen, Ron H. N. van Schaik, Anne‐Marie C. Dingemans, G. D. Marijn Veerman, Ron H. J. Mathijssen   +11 more
wiley   +1 more source

Pulmonary extranodal NK/T-cell lymphoma: A clinicopathological analysis of five patients.

Cytojournal
Li Q, Zhang Y, Sun H, Wang X, Wu D.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cutaneous T cell lymphoma

Nature Reviews Disease Primers, 2021
Primary cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of lymphomas that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. CTCL subtypes demonstrate a variety of clinical, histological, and molecular features, and can follow an indolent or a very aggressive course.
Dummer, Reinhard, Vermeer, Maarten H, Scarisbrick, Julia J, Kim, Youn H, Stonesifer, Connor, Tensen, Cornelis P, Geskin, Larisa J, Quaglino, Pietro, Ramelyte, Egle   +8 more
openaire   +4 more sources

Peripheral T‐cell lymphomas

Hematological Oncology, 2023
AbstractThe treatment of peripheral T‐cell lymphomas is challenging, as they often display a severe prognosis and lack effective treatment strategies. We will try to answer three burning questions: can we differentiate the initial treatment based on the histotype and the clinical presentation of peripheral T‐cell lymphoma patients?
Broccoli A., Zinzani P. L.
openaire   +3 more sources

Mantle cell lymphoma [PDF]

Current Treatment Options in Oncology, 2000
Mantle cell lymphoma is an aggressive non-Hodgkin's lymphoma that remains incurable with current chemotherapeutic approaches. Despite response rates to many regimens of 50% to 70%, the disease typically progresses after chemotherapy with a median survival time of approximately 3 years.
John J. Densmore, Michael E. Williams
openaire   +3 more sources

T‐Cell lymphomas [PDF]

Histopathology, 1986
In Europe and North America T-cell leukaemias and lymphomas are uncommon compared with tumours of B-lymphocytes although this disparity is probably exaggerated by under-recognition. Some neoplasms of T-lymphocytes have been reasonably well defined clinically and histologically.
openaire   +2 more sources